US HIV funding decisions on PEPFAR in 2017 will have critical effect on ability to reach 90-90-90 goals
First protease inhibitor combination pill maintains viral suppression
Adolescents with HIV do better in more prosperous African countries, even with treatment
France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic
Dutch study finds out whether gay men prefer daily or on-demand PrEP
Long-acting cabotegravir injection shows promise for HIV prevention
Doravirine combination pill looks good for initial HIV treatment
Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows
